NCT00865657View on ClinicalTrials.gov

A Relative Bioavailability Study of Alprazolam 3 mg Extended Release Tablets Under Non-fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

September 30, 2005

Study Completion Date

September 30, 2005

Conditions
Healthy
Interventions
DRUG

Alprazolam 3 mg Extended Release Tablets, single dose

A: Experimental Subjects received Alpharma formulated products under non-fasting conditions

DRUG

XANAX XR® 3 mg tablets, single dose

B: Active comparator Subjects received Pharmacia \& Upjohn Company formulated products under non-fasting conditions

Trial Locations (1)

58102

PRACS Institute, Ltd., Fargo

Sponsors

Lead Sponsor

Actavis Inc.
All Listed Sponsors
lead

Actavis Inc.

INDUSTRY

NCT00865657 - A Relative Bioavailability Study of Alprazolam 3 mg Extended Release Tablets Under Non-fasting Conditions | Biotech Hunter | Biotech Hunter